ATE269709T1 - Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff - Google Patents

Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff

Info

Publication number
ATE269709T1
ATE269709T1 AT99945371T AT99945371T ATE269709T1 AT E269709 T1 ATE269709 T1 AT E269709T1 AT 99945371 T AT99945371 T AT 99945371T AT 99945371 T AT99945371 T AT 99945371T AT E269709 T1 ATE269709 T1 AT E269709T1
Authority
AT
Austria
Prior art keywords
active
antihyperglycemic
tablet containing
sustained
blood sugar
Prior art date
Application number
AT99945371T
Other languages
English (en)
Inventor
Chih-Ming Chen
Xiu Xiu Cheng
Joseph Chou
Steve Jan
Original Assignee
Andrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals Inc filed Critical Andrx Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE269709T1 publication Critical patent/ATE269709T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99945371T 1998-08-31 1999-08-31 Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff ATE269709T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/143,876 US6099862A (en) 1998-08-31 1998-08-31 Oral dosage form for the controlled release of a biguanide and sulfonylurea
PCT/US1999/019978 WO2000012097A1 (en) 1998-08-31 1999-08-31 Controlled release tablet comprising a hypoglycemic drug and an antihyperglycemic drug

Publications (1)

Publication Number Publication Date
ATE269709T1 true ATE269709T1 (de) 2004-07-15

Family

ID=22506058

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99945371T ATE269709T1 (de) 1998-08-31 1999-08-31 Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff

Country Status (8)

Country Link
US (2) US6099862A (de)
EP (1) EP1107763B1 (de)
KR (1) KR20010079712A (de)
AT (1) ATE269709T1 (de)
AU (1) AU749550B2 (de)
CA (1) CA2341908A1 (de)
DE (1) DE69918310D1 (de)
WO (1) WO2000012097A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1063973B1 (de) 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Zweiphasiges kontrolliertes verabreichungssystem für hochlösliche arzneimittel und verwandtes verfahren
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
JP3382159B2 (ja) * 1998-08-05 2003-03-04 株式会社東芝 情報記録媒体とその再生方法及び記録方法
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
JP3212978B2 (ja) 1999-10-01 2001-09-25 普 山田 搬送車両
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
CA2407713A1 (en) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. A core formulation
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
EP1322158B1 (de) * 2000-10-02 2012-08-08 USV Ltd. Metformin enthaltende pharmazeutische Zusammensetzungen mit verzögerter Wirkstofffreigabe und Verfahren zu deren Herstellung
BR0115390A (pt) * 2000-11-03 2004-02-25 Andrx Corp Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
AU2005239716B2 (en) * 2000-11-03 2008-03-13 Andrx Labs, Llc Controlled Release Metformin Compositions
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
CA2725833A1 (en) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
NZ527930A (en) * 2001-03-16 2005-11-25 Andrx Pharmaceuticals Llc Controlled release sulfonylurea formulation
US20040156900A1 (en) * 2001-04-10 2004-08-12 Shanghvi Dilip Shantilal Time pulsed release composition
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
KR20040044992A (ko) * 2001-09-28 2004-05-31 썬 파마슈티컬 인더스트리스 리미티드 당뇨병 치료용 투여형태
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
US20030113366A1 (en) * 2001-12-14 2003-06-19 Macgregor Alexander Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
DE60323474D1 (de) * 2002-04-09 2008-10-23 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
WO2003096968A2 (en) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
AU2003241537A1 (en) * 2002-05-23 2003-12-12 Andrx Corporation Biguanide formulations
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20120034211A (ko) * 2002-09-20 2012-04-10 안드렉스 랩스 엘엘씨 약제학적 정제
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20050048119A1 (en) * 2002-09-20 2005-03-03 Avinash Nangia Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US20060002998A1 (en) * 2002-11-15 2006-01-05 Anupam Trehan Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
US7255891B1 (en) * 2003-02-26 2007-08-14 Advanced Cardiovascular Systems, Inc. Method for coating implantable medical devices
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
WO2004089343A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Water soluble tablets
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
WO2005041925A2 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption
EP1841414A1 (de) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazon- und metformin-formulierungen
US7588779B2 (en) * 2004-05-28 2009-09-15 Andrx Labs, Llc Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
WO2006030303A1 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Oral extended release dosage form comprising a high dose biguanide and a low dose sulfonylurea
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
US20060121108A1 (en) * 2004-12-02 2006-06-08 Prasad C K System and method for producing a directly compressible, high-potency formulation of metformin hydrochloride
CN1682737B (zh) * 2005-03-01 2010-12-29 沈阳药科大学 一种复方二甲双胍/格列吡嗪控释片及制备方法
PE20061245A1 (es) * 2005-03-30 2007-01-06 Generex Pharm Inc Composiciones para la transmision transmucosa oral de la metformina
WO2007027566A2 (en) 2005-09-02 2007-03-08 Genzyme Corporation Method for removing phosphate and polymer used therefore
CA2622693C (en) 2005-09-15 2015-05-05 Genzyme Corporation Sachet formulation for amine polymers
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
EP2066293A2 (de) 2006-09-29 2009-06-10 Genzyme Corporation Amid-dendrimer-zusammensetzungen
US8163799B2 (en) 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
TR200704897A1 (tr) * 2007-07-13 2009-02-23 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Uzatılmış salım sağlayan gliklazid formülasyonları@
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
AU2009279372A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
CN101810628B (zh) * 2010-04-13 2012-05-23 北京四环科宝制药有限公司 二甲双胍格列吡嗪片及其制备方法
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
PT2661266T (pt) * 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
FR2975300B1 (fr) 2011-05-19 2013-06-07 Thierry Breul Composition pharmaceutique a biodisponibilite amelioree
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
MX2014008190A (es) 2012-01-06 2015-02-04 Elcelyx Therapeutics Inc Composiciones de biguanida y métodos para tratar transtornos metabólicos.
WO2014154640A1 (en) 2013-03-25 2014-10-02 Sanovel Ilac Sanayi Ve Ticaret A.S. Controlled-release formulations comprising metformin and gliclazide
WO2014184742A1 (en) 2013-05-13 2014-11-20 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
WO2015073736A1 (en) 2013-11-13 2015-05-21 Arbor Pharmaceuticals, Llc Methods and compositions for treating adhd
WO2016016770A1 (en) 2014-07-26 2016-02-04 Wockhardt Limited A novel modified release pharmaceutical composition of sitagliptin or pharmaceutically acceptable salt thereof
CN105878204B (zh) * 2014-12-16 2019-04-09 合肥立方制药股份有限公司 一种盐酸二甲双胍渗透泵控释片及其制备方法
US20180362974A1 (en) 2015-07-02 2018-12-20 University Of Louisville Research Foundation, Inc. EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER
CN110856690B (zh) * 2018-08-22 2024-07-02 深圳善康医药科技股份有限公司 一种植入剂包膜及干燥装置
CN110856692B (zh) * 2018-08-22 2024-08-09 深圳善康医药科技股份有限公司 植入剂自动包膜装置及包膜工艺
CN110623933B (zh) * 2019-06-15 2022-07-01 德州德药制药有限公司 一种盐酸二甲双胍控释片及其制备方法
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法
CN116473935B (zh) * 2023-04-25 2025-02-21 南京易亨制药有限公司 一种格列吡嗪控释片

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2124256A1 (en) * 1971-05-15 1972-11-30 Dr Christian Brunnengraber Chemi sehe Fabrik & Co mbH 2400 Lübeck Oral antidiabetics - contg dicarboxylic amino acids
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
FR2243684B1 (de) * 1973-09-19 1977-01-28 Semb
US4080472A (en) * 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
DE2456666A1 (de) * 1974-11-30 1976-08-12 Henkel & Cie Gmbh Verfahren zum stabilisieren von calcium-hydrogenphosphat-dihydrat gegen hydrolyse
US3952741A (en) * 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
FR2320735A1 (fr) * 1975-08-12 1977-03-11 Dabis Georges Composition anti-cellulite
US4034758A (en) * 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4587117A (en) * 1983-06-06 1986-05-06 Alza Corporation Medical device for delivering drug to pH environments greater than 3.5
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4851229A (en) * 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
US4777049A (en) * 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
US4692336A (en) * 1984-03-19 1987-09-08 Alza Corporation Self controlled release device for administering beneficial agent to recipient
US4615698A (en) * 1984-03-23 1986-10-07 Alza Corporation Total agent osmotic delivery system
US4609374A (en) * 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4865598A (en) * 1985-08-16 1989-09-12 Alza Corporation Dispensing system for administering beneficial agent
US4704118A (en) * 1985-08-16 1987-11-03 Alza Corporation Ruminant dispensing device with thermo-activated memory
US4963141A (en) * 1985-08-16 1990-10-16 Alza Corporation Dispensing system for administering beneficial agent formulation to ruminants
US4849227A (en) * 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
US5141752A (en) * 1986-05-09 1992-08-25 Alza Corporation Delayed drug delivery device
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
FR2611500B1 (fr) * 1987-03-06 1990-05-04 Lipha Emploi de derives du biguanide dans la preparation de medicaments
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US4892739A (en) * 1988-04-25 1990-01-09 Ciba-Geigy Corporation Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5591454A (en) * 1989-09-05 1997-01-07 Alza Corporation Method for lowering blood glucose
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5071607A (en) * 1990-01-31 1991-12-10 Alza Corporatino Method and apparatus for forming a hole in a drug dispensing device
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
US5178866A (en) * 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
IE920040A1 (en) * 1991-01-09 1992-07-15 Alza Corp Bioerodible devices and compositions for diffusional release¹of agents
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5178867A (en) * 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5688518A (en) * 1992-02-27 1997-11-18 Alza Corporation Antidepressive therapy
US5185158A (en) * 1992-02-27 1993-02-09 Alza Corporation Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5512293A (en) * 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5674900A (en) * 1995-06-06 1997-10-07 Shaman Pharmaceuticals, Inc. Terpenoid-type quinones for treatment of diabetes
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US5691386A (en) * 1996-04-16 1997-11-25 Shaman Pharmaceuticals, Inc. Triterpenoid compound for the treatment of diabetes
WO1998010786A2 (en) * 1996-09-12 1998-03-19 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
US6399658B1 (en) * 1996-12-24 2002-06-04 Sumitomo Pharmaceuticals Co., Ltd. Composition containing ascorbic acid
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
ATE261935T1 (de) * 1997-12-08 2004-04-15 Bristol Myers Squibb Co Neue metformin salze und verfahren
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
CZ20011629A3 (cs) * 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků

Also Published As

Publication number Publication date
KR20010079712A (ko) 2001-08-22
US6284275B1 (en) 2001-09-04
WO2000012097A1 (en) 2000-03-09
DE69918310D1 (de) 2004-07-29
CA2341908A1 (en) 2000-03-09
EP1107763A1 (de) 2001-06-20
AU749550B2 (en) 2002-06-27
HK1039054A1 (en) 2002-04-12
EP1107763B1 (de) 2004-06-23
US6099862A (en) 2000-08-08
AU5797999A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
DE69918310D1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
ATE251449T1 (de) Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
CA2324493A1 (en) Controlled release oral tablet having a unitary core
DE60237372D1 (de) Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
GT199900151A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial.
EP0357369A3 (de) Verwendung von asymmetrischen Membranen in Abgabevorrichtungen
HUP9904174A2 (hu) Bőrön át történő adagoláshoz szánt gyógyszerkészítmények
DE69636104D1 (de) Orale pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreigabe von Protonenpumpen-Hemmern
EP1078628A3 (de) Aus vielen Einzeleinheiten zusammengesetzte tablettierte Dosisform
CA2145513A1 (en) Pharmaceutical Tablet Capable of Liberating One or More Drugs at Different Release Rates
CA2305762A1 (en) Delayed total release gastrointestinal drug delivery system
ATE264666T1 (de) Im magen verweilendes arzneimittel mit verzögerter wirkstoffabgabe
GB2340040A (en) Microparticles useful as ultrasonic contrast agents and for delivery of drugs into the bloodstream
DK0939626T3 (da) Galenisk form til forlænget frigivelse af milnacipran
DE3770937D1 (de) Tablette zur pharmazeutischen anwendung sukzessiver freisetzung.
WO2004000389A3 (en) Rapidly dissolving micro-perforator for drug delivery and other applications
ATE232100T1 (de) Gegen magensaft geschützte omeprazol- mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen
CA2416383A1 (en) Solution-, dispersion- or emulsion-producing film dermatics
WO2006022996A3 (en) Dosage form containing multiple drugs
ATE367803T1 (de) Subcutane implantate mit begrenzter initialer wirkstoff-freisetzung und deren anschliessende lineare veränderliche verlängerte freisetzung
NO992944L (no) Virkestoffbµrer for avgivelse av apomorfin i munnhulen
FI955979A0 (fi) Jatkuvasti vapauttava, kalvopäällysteinen astemitsoli- ja pseudoefedriinitabletti
ATE361060T1 (de) Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
ATE306910T1 (de) Tablette mit verlängerter wirkstoffabgabe im magen
WO2003096968A3 (en) Oral osmotic controlled drug delivery system

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties